Vijay KUMAR, Ajai SINGH, Vineet KUMAR, Syed Rizwan HUSSAIN, Abbas Ali MAHDI, Sabir ALI, Nazia RIZIVI, Manish YADAV, Mohammad Kaleem AHMAD

Identification of the cysteine-rich 61 (CYR61) gene variations in osteosarcoma patients

Background/aim: Osteosarcoma requires an angiogenesis process. CYR61 is one of the extracellular signaling molecules that promote angiogenesis, tumor growth, and the malignancy of osteosarcoma. In the present study, we investigate the CYR61 gene variations in osteosarcoma and their correlations with clinicopathological findings. Materials and methods: We performed variation analysis of the CYR61 gene in 58 patients with osteosarcoma. With an aim to ascertain the variety of variations in exons 2, 3, 4, and 5 of the CYR61 gene in osteosarcoma, we did a PCR-SSCP followed by DNA sequencing. Results: In osteosarcoma the CYR61 gene variations found were 18.96% (11/58) in exon 2, 3.44% (2/58) in exon 3, 8.62% (5/58) in exon 4, and 15.51% (9/58) in exon 5. In our variation analysis, we detected one missense variation in exon 2 (Arg47Trp), one silent variation in exon 3 (Lys152Lys), one missense variation in exon 4 (Phe213Leu), and two missense variations in exon 5 (Gly315Arg and Asp339Asn). The overall CYR61 variation frequency in exons 2, 3, 4, and 5 was determined to be 46.55% (27/58). Conclusion: Our study specifies the role of CYR61 gene variation in osteosarcoma. The result signifies that CYR61 might be used as a prognostic/diagnostic marker in osteosarcoma patients.

PDF

___

1. Harada S, Rodan GA. Control of osteoblast function and regulation of bone mass. Nature 2003; 15: 349-355.
2. Stiller CA. International patterns of cancer incidence in adolescents. Cancer Treat Rev 2007; 33: 631-645.
3. Coventry MB, Dahlin DC. Osteogenic sarcoma - A critical analysis of 430 cases. J Bone Joint Surg Am 1957; 39: 741-757.
4. Marcove RC, Mike V, Hajek JV, Levin AG, Hutter RV. Osteogenic sarcoma under the age of twenty-one. A review of one hundred and forty-five operative cases. J Bone Joint Surg Am 1970; 52: 411-423.
5. Bielack S, Carrle D, Casali PG; ESMO Guidelines Working Group. Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20 (Suppl. 4): 137-139.
6. Tang N, Song WX, Luo J, Haydon RC, He TC. Osteosarcoma development and stem cell differentiation. Clin Orthop Relat Res 2008; 466: 2114-2130
7. Damron TA, Ward WG, Stewart A. Osteosarcoma, chondrosarcoma, and Ewings sarcoma: National Cancer Data Base Report. Clin Orthop Relat Res 2007; 459: 40-47.
8. Kireeva ML, MO FE, Yang GP, Lau LF. CYR61, a product of a growth factor-inducible immediate-early gene, promotes cell proliferation, migration, and adhesion. Mol Cell Biol 1996; 16: 1326-1334.
9. Ries LAG, Smith MA, Gurney JG, Linet M, Tamra T, Young JL, Bunin GR. Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995. Bethesda, MD, USA: National Cancer Institute, SEER Program; 1999.
10. Omololu AB, Ogunbiyi JO, Ogunlade SO, Alonge TO, Adebisi A, Akang EE. Primary malignant bone tumour in a tropical African University teaching hospital. West Afr J Med 2002; 21: 291-293.
11. Chen PC, Cheng HC, Yang SF, Lin CW, Tang CH. The CCN family proteins: modulators of bone development and novel targets in bone-associated tumors. Biomed Res Int 2014; 2014: 437096.
12. Tan TW, Huang YL, Chang JT, Lin JJ, Fong YC, Kuo CC, Tsai CH, Chen YJ, Hsu HC, Cho DY et al. CCN3 increases BMP4 expression and bone mineralization in osteoblasts. J Cell Physiol 2012; 227: 2531-2541.
13. OBrien TP, Yang GP, Sanders L, Lau LF. Expression of CYR61, a growth factor inducible immediate-early gene. Mol Cell Biol 1990; 10: 3569-3577.
14. Frazier K, Williams S, Kothapalli D, Klapper H, Grotendorst GR. Stimulation of fibroblast cell growth, matrix production, and granulation tissue formation by connective tissue growth factor. J Invest Dermatol 1996; 107: 404-411.
15. Chen N, Chen CC, Lau LF. CYR61, a product of a growth factor-inducible immediate early gene, is associated with the extracellular matrix and the cell surface. Cell Growth Differ 1991; 2: 351-357.
16. Babic AM, Chen CC, Lau LF. Fisp12/mouse connective tissue growth factor mediates endothelial cell adhesion and migration through integrin αvβ3, promotes endothelial cell survival, and induces angiogenesis in vivo. Mol Cell Biol 1999; 19: 2958- 2966.
17. Tsai MS, Bogart DF, Li P, Mehmi I, Lupu R. Expression and regulation of CYR61 in human breast cancer cell lines. Oncogene 2002; 21: 964-973.
18. Leask A, Abraham DJ. All in the CCN family: essential matricellular signaling modulators emerge from the bunker. J Cell Sci 2006; 119: 4803-4810.
19. Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop 1980; 153: 106-120.
20. Bickels J, Jelinek BM, Shmookler BM, Neff RS, Malawar MM. Biopsy of musculoskeletal tumors. Current concepts. Clin Orthop Rel Res 1999; 368: 212-219.
21. Babic AM, Kireeva ML, Kolesnikova TV, Lau LF. CYR61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth. P Natl Acad Sci USA 1998; 95: 6355-6360.
22. Hussain SR, Babu SG, Raza ST, Singh P, Ahmed F, Naqvi H, Mahdi F. Screening of the c-kit gene missense mutation in invasive ductal carcinoma of breast among north Indian population. Mol Biol Rep 2012; 39: 9139-9144.
23. Perrot A, Schmitt KR, Roth EM, Stiller B, Posch MG, Browne EN, Timmann C, Horstmann RD, Berger F, Ozcelik C. CCN1 mutation is associated with atrial septal defect. Pediatr Cardiol 2015; 36: 295-299.
24. Huang J, Gao K, Lin J, Wang Q. MicroRNA-100 inhibits osteosarcoma cell proliferation by targeting CYR61. Tumour Biol 2014; 35: 1095-1100.
25. Chen J, Song Y, Yang J, Gong L, Zhao P, Zhang Y, Su H. The upregulation of cysteine-rich protein 61 induced by transforming growth factor beta enhances osteosarcoma cell migration. Mol Cell Biochem 2013; 384: 269-277.
26. Sandberg A. Random break points in normal individuals as well as genetic disorder patients. In: Sandberg AA, editor. The Chromosomes in Human Cancer and Leukemia. New York, NY, USA: Elsevier; 1980. pp. 567-596.
27. Murata H, Kusuzaki K, Takeshita H, Hirasawa Y, Ashihara T, Abe T, Inazawa J. Aberrations of chromosomes 1 and 17 in six human osteosarcoma cell lines using double-target fluorescence in situ hybridization. Cancer Genet Cytogenet 1998; 107: 7-10.
28. Wittig R, Nessling M, Will RD, Mollenhauer J, Salowsky R, Münstermann E, Schick M, Helmbach H, Gschwendt B, Korn B et al. Candidate genes for cross resistance against DNAdamaging drugs. Cancer Res 2002; 62: 6698-6705.
29. Gery S, Xie D, Yin D, Gabra H, Miller C, Wang H, Scott D, Yi WS, Popoviciu ML, Said JW el al. Ovarian carcinomas: CCN genes are aberrantly expressed and CCN1 promotes proliferation of these cells. Clin Cancer Res 2005; 11: 7243- 7254.
30. Lin MT, Chang CC, Chen ST, Chang HL, Su JL, Chau YP, Kuo ML. Cyr61 expression confers resistance to apoptosis in breast cancer MCF-7 cells by a mechanism of NF kappa B-dependent XIAP up-regulation. J Biol Chem 2004; 279: 24015-24023.
31. Fromigue O, Hamidouche Z, Vaudin P, Lecanda F, Patino A, Barbry P, Mari B, Marie PJ. CYR61 downregulation reduces osteosarcoma cell invasion, migration, and metastasis. J Bone Miner Res 2011; 26: 1533-1542.
32. Genini M, Schwalbe P, Scholl FA, Schafer BW. Isolation of genes differentially expressed in human primary myoblasts and embryonal rhabdomyosarcoma. Int J Cancer 1996; 66: 571-577.
33. Xie D, Yin D, Tong X, OKelly J, Mori A, Miller C, Black K, Gui D, Said JW, Koeffler HP. CYR61 is overexpressed in gliomas and involved in integrin-linked kinase-mediated Akt and betacatenin-TCF/Lef signalling pathways. Cancer Res 2004; 64: 1987-1996.
34. Holloway SE, Beck AW, Girard L, Jaber MR, Barnett CC Jr, Brekken RA, Fleming JB. Increased expression of CYR61 (CCN1) identified in peritoneal metastases from human pancreatic cancer. J Am Coll Surg 2005; 200: 371-377.